BioSpace News Archive

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) announces today that it will host its rescheduled corporate update conference call to review first quarter financial results and provide an update on corporate developments on Thursday, May 18, 2023, at 8:30am ET.

T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has rescheduled its first quarter 2023 financial results reporting to before market open on Monday, May 22, 2023.

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of its common stock.

Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 23rd Annual B. Riley Securities Institutional Investor Conference.

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that its Board of Directors has elected Luis A. Diaz, Jr., M.D. to serve as a director.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors.

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that the company’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for GAD is over 50% enrolled and dosed.

NANOBIOTIX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and reported financial results for the for the first quarter of 2023.

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced that it has commenced an underwritten public offering of $100.0 million of shares of common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase shares of common stock.

Abcam plc, a global leader in the supply of life science research tools, notes that its founder and former director Dr. Jonathan Milner has indicated he will take steps to call an extraordinary general meeting of the Company’s shareholders to elect himself to the Company’s Board of Directors as Executive Chairman.